Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of 32 systematic review(s)/meta-analysis(es). ^[1-32]
• Psoriasis: Ustekinumab demonstrated higher PASI75 (Health Assessment Questionnaire (HAQ)-Disability Index (DI)) and PASI90 response rates compared to placebo but was generally less effective than newer biologics (ixekizumab, bimekizumab, and risankizumab) for achieving PASI90 and PASI100 (Radiographic Damage (RD)).
• Psoriatic Arthritis: Ustekinumab showed improvements in ACR (PsARC) response criteria but was less effective in some studies compared to infliximab and golimumab. Its efficacy in preventing radiographic progression was lower than adalimumab and infliximab.
• Atopic Dermatitis: No significant differences were observed in treatment outcomes for Standard of Care (SOC) populations compared to dupilumab.
• Pediatric Psoriasis: Ustekinumab showed the best efficacy and lowest adverse effects among biologics in children.
• Ustekinumab was generally well-tolerated, with common adverse events including nasopharyngitis, headaches, and upper respiratory tract infections. Serious adverse events were comparable to placebo.
• Grade 3 and 4 adverse effects, both immunological and non-immunological, were noted but were overall well-tolerated.
• There was no significant increase in the risk of major adverse cardiovascular events (MACE) compared to placebo, and the safety profile was similar to other biologics, including adalimumab, infliximab, and secukinumab.
• There is no population types or subgroups information available in the reviewed studies.